Viatris

VIATRIS™ is a new global healthcare company formed by the merger of Mylan and Upjohn, a division of Pfizer, officially announced on November 16, 2020.Viatris' global portfolio includes top-tier iconic branded products as well as major global brands; generics, including branded generics and complex generics; biosimilars; and over-the-counter products across a wide range of therapeutic areas.Viatris has one of the strongest global commercial infrastructures in the industry, with balanced business coverage in North America, Europe, Asia-Pacific, and emerging markets. Viatris' high-quality global manufacturing capabilities, scientific excellence, and extensive supply chain network mean the company is uniquely positioned to enhance global patient access to medicines.The merger between Mylan and Upjohn was announced on July 29, 2019, and received final regulatory approval on October 30, 2020. Viatris began regular trading on NASDAQ under the ticker symbol VTRS on November 17, 2020, at the start of the trading day (the first full trading day after the closing).